Azficel-T
Appearance
This article provides insufficient context for those unfamiliar with the subject.(March 2021) |
Clinical data | |
---|---|
Trade names | Laviv |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Intradermal |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
DrugBank | |
UNII |
Azficel-T, sold under the brand name Laviv, is a cell therapy product for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.[1][2][3] It consists of fibroblasts harvested from the patient's own skin.[2]
It was approved for medical use in the United States in June 2011.[2]
References
[edit]- ^ a b "Laviv (Azficel-T)". U.S. Food and Drug Administration (FDA). 22 July 2017. Archived from the original on 16 December 2019. Retrieved 1 April 2020.
- ^ a b c d "Autologous Fibroblasts". U.S. Food and Drug Administration (FDA). 29 June 2017. Archived from the original on 22 July 2017. Retrieved 1 April 2020.
{{cite web}}
: CS1 maint: unfit URL (link) - ^ "Laviv (azficel-T) Suspension for Intradermal Injection" (PDF). Food and Drug Administration. Archived from the original on 14 December 2019. Retrieved 2 April 2020.
Further reading
[edit]- Smith SR, Munavalli G, Weiss R, Maslowski JM, Hennegan KP, Novak JM (July 2012). "A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles". Dermatol Surg. 38 (7 Pt 2): 1234–43. doi:10.1111/j.1524-4725.2012.02349.x. PMID 22409385. S2CID 24901992.
{{cite journal}}
: CS1 maint: overridden setting (link)
External links
[edit]- "Laviv (azficel-T)". Medscape. 28 September 2019.
- Clinical trial number NCT02120781 for "Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia" at ClinicalTrials.gov